Consequently, the concept of PD-L1 expression induced by [177Lu]Lu-DOTA-iPD-L1 (radiation) and the subsequent blockade by the administration of anti-PD-L1/PD-1 or PD-L1 inhibitor agents may represent a potent therapeutic modality, particularly in the context of triple-negative breast cancer [12]. This evidence concerns the gene PDCD1 and triple-negative breast carcinoma.